Key Highlights
- Net loss was USD 32.4 million, compared with USD 26.0 million.
- Research and development expenses were USD 26.1 million.
- Cash, equivalents and short-term investments were USD 201.7 million.
- Grant Revenue was USD 20 thousand, compared with USD 209 thousand.
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) reported third quarter 2026 results with a net loss of USD 32.4 million, compared with USD 26.0 million in the third quarter of 2025. Reported EPS was negative USD 0.27 and revenue was USD 20.00 thousand, compared with estimates of EPS of negative USD 0.24 and revenue of USD 56.50 thousand.
The company reported grant revenue of USD 20 thousand for the quarter, compared with USD 209 thousand. Grant revenue for all periods presented relates to work for the National Institutes of Health. The filing states that the company's Alpha therapy Business is in the clinical stage and that none of its revenues reflect sales of its alpha therapy candidates.
Operating Expenses
Research and development expenses were USD 26.1 million, compared with USD 20.3 million, an increase of USD 5.8 million. For the nine months, Research and Development expenses were USD 69.0 million, compared with USD 51.3 million, an increase of USD 17.7 million.
General and administrative expenses were USD 8.3 million, compared with USD 7.7 million, an increase of USD 0.6 million. For the nine months, general and administrative expenses were USD 23.0 million, compared with USD 23.3 million, a decrease of USD 0.3 million.
Losses
The operating loss was USD 34.3 million, compared with USD 27.9 million, and the nine month operating loss was USD 91.9 million, compared with USD 73.7 million. Net loss from continuing operations was USD 32.4 million, compared with USD 26.0 million. For the nine months, net loss was USD 85.4 million, compared with USD 65.6 million, and net loss from continuing operations was USD 85.6 million, compared with USD 66.1 million.
Liquidity
The filing states that the company has had a history of operating losses and an absence of significant recurring cash inflows from revenue, and it assesses Liquidity by its ability to generate cash to fund operating, investing and financing activities. As of September 30, 2026, the company had cash, cash equivalents and short-term investments of USD 201.7 million and a total accumulated Deficit of USD 420.3 million. The company stated that it believes this amount is sufficient to fund its current planned operations into 2028, though it may raise additional Capital through Equity offerings, debt financings, collaborations, strategic alliances, marketing, distribution or licensing arrangements and government funding and grants.
Net cash used in Operating Activities for the nine months increased by USD 25.6 million compared with the same period in 2025, primarily due to a USD 19.8 million increase in net loss and USD 9.7 million from changes in operating Assets and liabilities, partially offset by a USD 3.8 million increase in non-cash activities. Net cash provided by financing activities was USD 164.7 million, compared with USD 10.3 million, primarily from proceeds of the sale of common stock and pre-funded warrants under the 2026 Offering and the 2024 ATM Agreement, respectively.
NIH Grants, Expenses and Funding
Perspective Therapeutics reported USD 20 thousand of NIH grant revenue, research and development expenses of USD 26.1 million and USD 201.7 million in cash, equivalents and short term investments. The filing places the accumulated deficit at USD 420.3 million and attributes USD 164.7 million of nine month financing proceeds to the 2026 Offering and the ATM Agreement.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...